Carlyle Group Inc. Invests $227,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Carlyle Group Inc. acquired a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,620 shares of the company’s stock, valued at approximately $227,000. Spyre Therapeutics accounts for approximately 0.0% of Carlyle Group Inc.’s holdings, making the stock its 27th biggest holding.

Other hedge funds have also bought and sold shares of the company. SG Americas Securities LLC bought a new stake in Spyre Therapeutics during the second quarter valued at $130,000. EFG Asset Management North America Corp. bought a new stake in shares of Spyre Therapeutics during the 2nd quarter valued at about $869,000. Bank of New York Mellon Corp acquired a new stake in Spyre Therapeutics during the second quarter worth approximately $2,767,000. Rhumbline Advisers bought a new stake in Spyre Therapeutics in the second quarter worth approximately $1,220,000. Finally, TD Asset Management Inc acquired a new position in Spyre Therapeutics in the second quarter valued at approximately $827,000. Institutional investors own 80.39% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on SYRE shares. Evercore ISI began coverage on shares of Spyre Therapeutics in a research report on Tuesday, July 16th. They set an “outperform” rating for the company. Wedbush assumed coverage on shares of Spyre Therapeutics in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $45.00 price target for the company. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $43.43.

Spyre Therapeutics Trading Up 3.2 %

Spyre Therapeutics stock opened at $29.36 on Monday. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -0.41 and a beta of 2.92. The firm’s fifty day moving average price is $27.84 and its two-hundred day moving average price is $32.05. Spyre Therapeutics, Inc. has a 1-year low of $8.43 and a 1-year high of $47.97.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.86) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.04. On average, research analysts forecast that Spyre Therapeutics, Inc. will post -3.68 EPS for the current year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).